- Home
- DNTH vs DNA Comparison
DNTH vs DNA Comparison
Compare DNTH & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- DNA
- Stock Information
- Founded
- DNTH 2015
- DNA 2008
- Country
- DNTH United States
- DNA United States
- Employees
- DNTH N/A
- DNA N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DNTH Health Care
- DNA Health Care
- Exchange
- DNTH Nasdaq
- DNA Nasdaq
- Market Cap
- DNTH 568.6M
- DNA 466.4M
- IPO Year
- DNTH N/A
- DNA N/A
- Fundamental
- Price
- DNTH $18.85
- DNA $12.69
- Analyst Decision
- DNTH Strong Buy
- DNA Sell
- Analyst Count
- DNTH 8
- DNA 3
- Target Price
- DNTH $53.00
- DNA $9.67
- AVG Volume (30 Days)
- DNTH 315.6K
- DNA 1.6M
- Earning Date
- DNTH 08-07-2025
- DNA 08-07-2025
- Dividend Yield
- DNTH N/A
- DNA N/A
- EPS Growth
- DNTH N/A
- DNA N/A
- EPS
- DNTH N/A
- DNA N/A
- Revenue
- DNTH $6,524,000.00
- DNA $237,417,000.00
- Revenue This Year
- DNTH N/A
- DNA N/A
- Revenue Next Year
- DNTH N/A
- DNA $15.81
- P/E Ratio
- DNTH N/A
- DNA N/A
- Revenue Growth
- DNTH 102.36
- DNA 13.76
- 52 Week Low
- DNTH $13.37
- DNA $5.00
- 52 Week High
- DNTH $32.27
- DNA $16.85
- Technical
- Relative Strength Index (RSI)
- DNTH 54.07
- DNA 79.41
- Support Level
- DNTH $17.27
- DNA $8.21
- Resistance Level
- DNTH $19.46
- DNA $10.02
- Average True Range (ATR)
- DNTH 1.07
- DNA 0.87
- MACD
- DNTH 0.15
- DNA 0.39
- Stochastic Oscillator
- DNTH 76.74
- DNA 88.09
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.